Letters
Risks of gene therapy should be weighed against lack of alternatives for many diseases
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7494.791-a (Published 31 March 2005) Cite this as: BMJ 2005;330:791
- Robert E MacLaren, MRC research fellow,
- Robin R Ali, professor of human molecular genetics,
- Adrian J Thrasher, professor of paediatric immunology
- Division of Molecular Therapy, Institute of Ophthalmology, University College London, London EC1V 9EL
- Molecular Immunology Unit, Institute of Child Health, UCL, London WC1N 1EH
EDITOR—Kimmelman provided a comprehensive discussion about the risks and ethics of gene therapy.1 We certainly cannot predict the future, but the risks should be weighed against the complete lack of alternative options for many of the diseases discussed.
Artwork of gene therapy
Credit: ©JIM DOWDALLS/SPL
The two cases of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.